IPH Fundamental Analysis - INNATE PHARMA SA

Name: INNATE PHARMA SA (IPH) Stock
Brand: INNATE PHARMA SA
Rating: 3.5 (3 reviews)

Fundamental Rating

Overall IPH gets a fundamental rating of 1 out of 10. We evaluated IPH against 74 industry peers in the Biotechnology industry. Both the profitability and financial health of IPH have multiple concerns. IPH does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IPH has reported negative net income.

IPH had a negative operating cash flow in the past year.

IPH had negative earnings in each of the past 5 years.

In the past 5 years IPH always reported negative operating cash flow.

1.2 Ratios

IPH has a Return On Assets of -49.55%. This is in the lower half of the industry: IPH underperforms 63.51% of its industry peers.

With a Return On Equity value of -895.24%, IPH is not doing good in the industry: 70.27% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-49.55%
ROE	-895.24%
ROIC	N/A

ROA(3y)-25.61%

ROA(5y)-23.47%

ROE(3y)-227.3%

ROE(5y)-154.41%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IPH has a Gross Margin (49.52%) which is in line with its industry peers.

IPH's Gross Margin has declined in the last couple of years.

The Profit Margin and Operating Margin are not available for IPH so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	49.52%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.49%

GM growth 5Y-4.49%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IPH does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for IPH has been increased compared to 1 year ago.

IPH has more shares outstanding than it did 5 years ago.

The debt/assets ratio for IPH is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -6.22, we must say that IPH is in the distress zone and has some risk of bankruptcy.

IPH's Altman-Z score of -6.22 is on the low side compared to the rest of the industry. IPH is outperformed by 72.97% of its industry peers.

A Debt/Equity ratio of 11.55 is on the high side and indicates that IPH has dependencies on debt financing.

IPH has a worse Debt to Equity ratio (11.55) than 70.27% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	11.55
Debt/FCF	N/A
Altman-Z	-6.22

ROIC/WACCN/A

WACC6.74%

2.3 Liquidity

IPH has a Current Ratio of 2.21. This indicates that IPH is financially healthy and has no problem in meeting its short term obligations.

IPH has a Current ratio of 2.21. This is comparable to the rest of the industry: IPH outperforms 48.65% of its industry peers.

A Quick Ratio of 2.21 indicates that IPH has no problem at all paying its short term obligations.

IPH has a Quick ratio of 2.21. This is comparable to the rest of the industry: IPH outperforms 58.11% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.21
Quick Ratio	2.21

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.42%.

Looking at the last year, IPH shows a very negative growth in Revenue. The Revenue has decreased by -75.86% in the last year.

Measured over the past years, IPH shows a very negative growth in Revenue. The Revenue has been decreasing by -28.80% on average per year.

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.82%

Revenue 1Y (TTM)-75.86%

Revenue growth 3Y1.38%

Revenue growth 5Y-28.8%

Sales Q2Q%-79.85%

3.2 Future

Based on estimates for the next years, IPH will show a decrease in Earnings Per Share. The EPS will decrease by -3.57% on average per year.

Based on estimates for the next years, IPH will show a very strong growth in Revenue. The Revenue will grow by 43.06% on average per year.

EPS Next Y-32.84%

EPS Next 2Y-10.27%

EPS Next 3Y-3.57%

EPS Next 5YN/A

Revenue Next Year-26.21%

Revenue Next 2Y3.03%

Revenue Next 3Y2.3%

Revenue Next 5Y43.06%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

IPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPH. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

IPH's earnings are expected to decrease with -3.57% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-10.27%

EPS Next 3Y-3.57%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IPH does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INNATE PHARMA SA

EPA:IPH (11/11/2025, 7:00:00 PM)

1.71

-0.16 (-8.56%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-17 2025-09-17/bmo

Earnings (Next)11-13 2025-11-13/bmo

Inst Owners10.18%

Inst Owner ChangeN/A

Ins Owners0.92%

Ins Owner ChangeN/A

Market Cap157.61M

Revenue(TTM)6.00M

Net Income(TTM)-46.05M

Analysts80

Price Target5.46 (219.3%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-1.65%

PT rev (3m)-3.16%

EPS NQ rev (1m)0%

EPS NQ rev (3m)N/A

EPS NY rev (1m)-230.42%

EPS NY rev (3m)-711.36%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-18.95%

Revenue NY rev (3m)-67.69%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	26.27
P/FCF	N/A
P/OCF	N/A
P/B	30.64
P/tB	30.64
EV/EBITDA	N/A

EPS(TTM)-0.55

EYN/A

EPS(NY)-0.5

Fwd EYN/A

FCF(TTM)-0.45

FCFYN/A

OCF(TTM)-0.45

OCFYN/A

SpS0.07

BVpS0.06

TBVpS0.06

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-49.55%
ROE	-895.24%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	49.52%
FCFM	N/A

ROA(3y)-25.61%

ROA(5y)-23.47%

ROE(3y)-227.3%

ROE(5y)-154.41%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.49%

GM growth 5Y-4.49%

F-Score1

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	11.55
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	10.84%
Cap/Sales	2.82%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.21
Quick Ratio	2.21
Altman-Z	-6.22

F-Score1

WACC6.74%

ROIC/WACCN/A

Cap/Depr(3y)22.77%

Cap/Depr(5y)23.45%

Cap/Sales(3y)3.3%

Cap/Sales(5y)8.22%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.82%

EPS Next Y-32.84%

EPS Next 2Y-10.27%

EPS Next 3Y-3.57%

EPS Next 5YN/A

Revenue 1Y (TTM)-75.86%

Revenue growth 3Y1.38%

Revenue growth 5Y-28.8%

Sales Q2Q%-79.85%

Revenue Next Year-26.21%

Revenue Next 2Y3.03%

Revenue Next 3Y2.3%

Revenue Next 5Y43.06%

EBIT growth 1Y-31.37%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year283.08%

EBIT Next 3Y30.44%

EBIT Next 5YN/A

FCF growth 1Y-25.63%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-29.1%

OCF growth 3YN/A

OCF growth 5YN/A

INNATE PHARMA SA / IPH.PA FAQ

Can you provide the ChartMill fundamental rating for INNATE PHARMA SA?

ChartMill assigns a fundamental rating of 1 / 10 to IPH.PA.

What is the valuation status of INNATE PHARMA SA (IPH.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA (IPH.PA). This can be considered as Overvalued.

Can you provide the profitability details for INNATE PHARMA SA?

INNATE PHARMA SA (IPH.PA) has a profitability rating of 0 / 10.

How financially healthy is INNATE PHARMA SA?

The financial health rating of INNATE PHARMA SA (IPH.PA) is 2 / 10.

INNATE PHARMA SA (IPH.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

INNATE PHARMA SA / IPH.PA FAQ

Can you provide the ChartMill fundamental rating for INNATE PHARMA SA?

What is the valuation status of INNATE PHARMA SA (IPH.PA) stock?

Can you provide the profitability details for INNATE PHARMA SA?

How financially healthy is INNATE PHARMA SA?